• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Pharmacokinetics of WR-1065 in mouse tissue following treatment with WR-2721.

作者信息

Utley J F, Seaver N, Newton G L, Fahey R C

出版信息

Int J Radiat Oncol Biol Phys. 1984 Sep;10(9):1525-8. doi: 10.1016/0360-3016(84)90495-4.

DOI:10.1016/0360-3016(84)90495-4
PMID:6090355
Abstract

Levels of reduced glutathione (GSH) and N-(2-mercaptoethyl)-1,3-diaminopropane (WR-1065) were measured in tissues of Balb/c mouse bearing EMT6 tumors at time intervals ranging from 5 min to 48 hr after i.v. injection of S-2-(3-aminopropylamino)ethyl phosphorothioate (WR-2721) at 500 mg per kg. In all tissues examined (liver, kidney, lung, heart, muscle, brain, tumor, spleen, and salivary gland), maximal WR-1065 levels occurred 5-15 min after injection, with levels in liver, kidney, lung, and salivary gland exceeding one mumole per gm. The post-maximum decline in WR-1065 varied markedly with tissue, lung exhibiting a 6-fold drop by 30 min and salivary gland falling only 15% after 3 hr. In a mouse treated with carbon-14 labeled WR-2721 it was found after 15 min that WR-1065 accounted for over half of the total drug in all tissues except tumor, where it accounted for a third of the total drug. There was no evidence that GSH levels were substantially altered by WR-2721 treatment. The results provide the first direct evidence supporting the widely held view that WR-2721 treatment results in intracellular WR-1065 and they demonstrate that high levels of WR-1065 occur very soon after i.v. injection.

摘要

相似文献

1
Pharmacokinetics of WR-1065 in mouse tissue following treatment with WR-2721.
Int J Radiat Oncol Biol Phys. 1984 Sep;10(9):1525-8. doi: 10.1016/0360-3016(84)90495-4.
2
Distribution of 35S-labeled WR-2721 in normal and malignant tissues of the mouse1,2.35S标记的WR-2721在小鼠正常组织和恶性组织中的分布1,2 。
Radiat Res. 1976 Nov;68(2):284-91.
3
Human pharmacokinetics of WR-2721.WR-2721的人体药代动力学。
Int J Radiat Oncol Biol Phys. 1986 Aug;12(8):1501-4. doi: 10.1016/0360-3016(86)90203-8.
4
Radioprotection of normal tissues against gamma rays and cyclotron neutrons with WR-2721: LD50 studies and 35S-WR-2721 biodistribution.WR-2721对正常组织的γ射线和回旋加速器中子辐射防护作用:半数致死剂量研究及35S-WR-2721生物分布
Radiat Res. 1984 Mar;97(3):598-607.
5
Tissue levels of WR-1065, the active metabolite of amifostine (Ethyol), are equivalent following intravenous or subcutaneous administration in cynomolgus monkeys.氨磷汀(依硫磷)的活性代谢产物WR-1065在食蟹猴体内经静脉或皮下给药后,其组织水平相当。
Oncology. 2004;67(3-4):187-93. doi: 10.1159/000081316.
6
Comparison of the protective effects of three phosphorothioate radioprotectors in the RIF-1 tumor.三种硫代磷酸酯辐射防护剂对RIF-1肿瘤的保护作用比较。
Radiat Res. 1986 Nov;108(2):167-75.
7
Biodistribution of the radioprotective drug 35S-labeled 3-amino-2-hydroxypropyl phosphorothioate (WR77913).放射防护药物35S标记的3-氨基-2-羟丙基硫代磷酸酯(WR77913)的生物分布。
Radiat Res. 1985 Apr;102(1):130-7.
8
Metabolic pathways of WR-2721 (ethyol, amifostine) in the BALB/c mouse.WR-2721(乙磺半胱氨酸,氨磷汀)在BALB/c小鼠体内的代谢途径。
Drug Metab Dispos. 1994 Nov-Dec;22(6):895-902.
9
Alkaline phosphatase promotes radioprotection and accumulation of WR-1065 in V79-171 cells incubated in medium containing WR-2721.碱性磷酸酶可促进在含有WR-2721的培养基中孵育的V79-171细胞对辐射的防护作用以及WR-1065的积累。
Int J Radiat Biol Relat Stud Phys Chem Med. 1985 Jan;47(1):23-7. doi: 10.1080/09553008514550041.
10
Variation in normal tissue responsiveness to WR-2721.
Int J Radiat Oncol Biol Phys. 1984 Sep;10(9):1537-9. doi: 10.1016/0360-3016(84)90498-x.

引用本文的文献

1
Diselenide-based nanoparticles enhancing the radioprotection to the small intestine of mice.基于二硒化物的纳米颗粒增强对小鼠小肠的辐射防护作用。
J Nanobiotechnology. 2025 Mar 22;23(1):236. doi: 10.1186/s12951-025-03276-3.
2
Cancer Incidence in C3H Mice Protected from Lethal Total-Body Radiation after Amifostine.氨磷汀保护下的 C3H 小鼠的辐射致癌性
Radiat Res. 2018 May;189(5):490-496. doi: 10.1667/RR14987.1. Epub 2018 Mar 12.
3
The radioprotective agent WR1065 protects cells from radiation damage by regulating the activity of the Tip60 acetyltransferase.
辐射防护剂WR1065通过调节Tip60乙酰转移酶的活性来保护细胞免受辐射损伤。
Int J Biochem Mol Biol. 2011;2(4):295-302. Epub 2011 Oct 20.
4
Zebrafish as a model system to screen radiation modifiers.斑马鱼作为筛选辐射调节剂的模型系统。
Curr Genomics. 2007 Sep;8(6):360-9. doi: 10.2174/138920207783406497.
5
In vivo mesna and amifostine do not prevent chloroacetaldehyde nephrotoxicity in vitro.体内使用美司钠和氨磷汀并不能预防体外氯乙醛的肾毒性。
Pediatr Nephrol. 2008 Apr;23(4):611-8. doi: 10.1007/s00467-007-0689-6. Epub 2008 Jan 18.
6
Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome.氨磷汀:关于其在接受化疗或放疗的癌症患者中作为细胞保护剂的临床现状及其在骨髓增生异常综合征中的潜在治疗应用的最新情况。
Drugs. 2001;61(5):641-84. doi: 10.2165/00003495-200161050-00012.
7
A risk-benefit assessment of amifostine in cytoprotection.氨磷汀细胞保护作用的风险效益评估。
Drug Saf. 1999 Nov;21(5):367-87. doi: 10.2165/00002018-199921050-00003.
8
Influence of single and multiple doses of amifostine on the efficacy and the pharmacokinetics of carboplatin in mice.单剂量和多剂量氨磷汀对小鼠体内卡铂疗效及药代动力学的影响。
Br J Cancer. 1997;75(10):1439-46. doi: 10.1038/bjc.1997.247.
9
Amifostine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector.氨磷汀。对其药效学和药代动力学特性以及作为辐射防护剂和细胞毒性化学保护剂的治疗潜力的综述。
Drugs. 1995 Dec;50(6):1001-31. doi: 10.2165/00003495-199550060-00008.
10
WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach.与其他化学保护剂相比,WR2721作为顺铂和卡铂诱导副作用的调节剂:一种分子方法。
Cancer Chemother Pharmacol. 1993;33(2):93-106. doi: 10.1007/BF00685326.